Seeking Alpha

Mallinckrodt says its acute pain drug met primary endpoints in Phase III testing

  • Mallinckrodt (MNK +2.3%) trades up after saying its investigational drug MNK-795 showed statistically significant improvement in pain scores compared to a placebo during Phase III testing for treatment of acute pain following bunion removals.
  • The drug's New Drug Application was accepted by the FDA in July and granted priority review.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs